Literature DB >> 30833001

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.

Emanuelle M Rizk1, Robyn D Gartrell1, Luke W Barker2, Camden L Esancy1, Grace G Finkel2, Darius D Bordbar2, Yvonne M Saenger3.   

Abstract

Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8+ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Checkpoint inhibition; Immunohistochemistry; Immunotherapy; Predictive and prognostic biomarkers

Year:  2019        PMID： 30833001      PMCID： PMC6497069          DOI： 10.1016/j.hoc.2018.12.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  75 in total

1.  PD-L1 as a biomarker in NSCLC: challenges and future directions.

Authors:  Matthen Mathew; Rachael A Safyan; Catherine A Shu
Journal:  Ann Transl Med       Date:  2017-09

2.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Authors:  F Stephen Hodi; Marcus Butler; Darryl A Oble; Michael V Seiden; Frank G Haluska; Andrea Kruse; Suzanne Macrae; Marybeth Nelson; Christine Canning; Israel Lowy; Alan Korman; David Lautz; Sara Russell; Michael T Jaklitsch; Nikhil Ramaiya; Teresa C Chen; Donna Neuberg; James P Allison; Martin C Mihm; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

3.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

4.  The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.

Authors:  Anton Uryvaev; Maria Passhak; Dov Hershkovits; Edmond Sabo; Gil Bar-Sela
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

5.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.

Authors:  M C Mihm; C G Clemente; N Cascinelli
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

Review 6.  Prognostic versus predictive value of biomarkers in oncology.

Authors:  C N A M Oldenhuis; S F Oosting; J A Gietema; E G E de Vries
Journal:  Eur J Cancer       Date:  2008-04-07       Impact factor: 9.162

7.  PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.

Authors:  Malaka Ameratunga; Khashayar Asadi; Xihui Lin; Marzena Walkiewicz; Carmel Murone; Simon Knight; Paul Mitchell; Paul Boutros; Thomas John
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

8.  Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression.

Authors:  Jianzhen Lin; Junyu Long; Xueshuai Wan; Jingci Chen; Yi Bai; Anqiang Wang; Xiaobo Yang; Yan Wu; Simon C Robson; Xinting Sang; Haitao Zhao
Journal:  BMC Cancer       Date:  2018-07-28       Impact factor: 4.430

Review 9.  Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.

Authors:  Krijn K Dijkstra; Paula Voabil; Ton N Schumacher; Emile E Voest
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

10.  Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.

Authors:  H Raza Ali; Aliakbar Dariush; Elena Provenzano; Helen Bardwell; Jean E Abraham; Mahesh Iddawela; Anne-Laure Vallier; Louise Hiller; Janet A Dunn; Sarah J Bowden; Tamas Hickish; Karen McAdam; Stephen Houston; Mike J Irwin; Paul D P Pharoah; James D Brenton; Nicholas A Walton; Helena M Earl; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2016-02-16       Impact factor: 6.466
View more
  6 in total

Review 1.  Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Authors:  Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger
Journal:  Am J Clin Dermatol       Date:  2020-02       Impact factor: 7.403

Review 2.  Electrochemical biosensors for measurement of colorectal cancer biomarkers.

Authors:  Wenxian Zhang; Guangchun Xiao; Jun Chen; Li Wang; Qiongzheng Hu; Jian Wu; Wenhong Zhang; Ming Song; Jinwei Qiao; Chonghai Xu
Journal:  Anal Bioanal Chem       Date:  2021-03-05       Impact factor: 4.142

3.  Promoting Best Practice in Cancer Care in Sub Saharan Africa.

Authors:  Karishma Sharma; Shahin Sayed; Mansoor Saleh
Journal:  Front Med (Lausanne)       Date:  2022-07-06

Review 4.  Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle.

Authors:  Yuan Zhuang; Chang Liu; Jiaqing Liu; Guang Li
Journal:  Onco Targets Ther       Date:  2020-01-07       Impact factor: 4.147

5.  PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma.

Authors:  Zhao Yang; Lei Zhang; Jianwei Liu; Lixue Yang; Hui Xue; Shilei Bai; Kui Wang
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

6.  Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.

Authors:  Juan Francisco Peña-Cardelles; José Juan Pozo-Kreilinger; Giovanna Roncador; Jesús Esteban-Hernández; José Ernesto Moro-Rodríguez; Ana Sastre-Perona; Beatriz Castelo-Fernández; José Luis Cebrián-Carretero
Journal:  Biomedicines       Date:  2022-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.